Survodutide

Investigated uses

• Obesity and metabolic/liver disease in clinical development.

Mechanism and hypotheses

• Survodutide is a dual GLP-1/glucagon receptor agonist evaluated in randomized obesity trials.
• Hypothesized: The balance of appetite suppression, glucagon signaling and liver/metabolic effects remains under clinical study.

Human evidence

• A phase 2 randomized trial enrolled 387 adults and tested weekly target doses through 46 weeks; weight loss was greater than placebo. Limitations: Rapid escalation contributed to tolerability-related discontinuation; long-term safety remains investigational.

Safety highlights

• Gastrointestinal adverse events predominated and were concentrated during escalation.
• Long-term rare-event and cardiovascular safety remain under investigation.

Regulatory context

No FDA-approved product matching the exact catalog presentation was identified in this review.